Femasys Q3 sales up 31% to $729K; FDA clears FemBloc final pivotal trial; $12M financing extends runway

FEMASYS INC

2025-Q3 EPS reported -$0.46 vs consensus -$0.13 ▼ miss (-246.9%)

Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.
Sales rose 31.4% YoY to $729,394, driven by FemBloc product sales.
FDA IDE approval to commence final phase of FemBloc pivotal trial for U.S. approval.
Closed $12M secured convertible note offering with warrants for up to $58M total potential funding.
Cash $4.6M at Q3 end; with recent financing, runway extended into September 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.